Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$29.31 USD

29.31
242,085

+0.02 (0.07%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CPSI or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Why You Shouldn't Bet Against Omnicell (OMCL) Stock

by Zacks Equity Research

Omnicell (OMCL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Is Omnicell (OMCL) Down 5% Since Last Earnings Report?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strong segmental performance in Q4.

Omnicell-Geisinger Deal Improves Patient Care via Automation

by Zacks Equity Research

Omnicell's (OMCL) XT series Automated Dispensing Systems partners with Geisinger to streamline nursing workflow and improve patient care.

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Omnicell (OMCL) Misses Q4 Earnings Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of -1.28% and 2.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu

by Zacks Equity Research

Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.

Here's Why You Should Retain Edwards Lifesciences Stock Now

by Zacks Equity Research

Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Hologic (HOLX) gains from several positive developments.

Integra Announces Preliminary Q4 Results, Share Buyback Plan

by Zacks Equity Research

Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now

by Zacks Equity Research

Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.

Trina Mukherjee headshot

5 Promising Growth Stocks in MedTech to Invest in 2020

by Trina Mukherjee

We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

by Zacks Equity Research

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Varian (VAR) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Varian (VAR) gains from several positive developments.

Amedisys Gains on Favorable Demography, New Hospice Buyouts

by Zacks Equity Research

Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

by Zacks Equity Research

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

by Zacks Equity Research

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Here's Why You Should Add STERIS (STE) to Portfolio Now

by Zacks Equity Research

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

Urmimala Biswas headshot

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

by Urmimala Biswas

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

by Zacks Equity Research

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

by Zacks Equity Research

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.